• Facing
    Metastatic Cancer
    • Is Metastatic Cancer Curable?
    • Access to the Right Treatment
    • Registering with Cancer Commons
    • Enroll in XCELSIOR
    • Can a Virtual Tumor Board Help?
    • Get Help With Your Treatment Plan
  • New Cancer Research
    & Perspectives
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • Our Story
    • It Started in 1998…
    • We’re Here to Help
    • Why We Go to Work Each Day
    • Our Services
    • Meet the Team
    • Why we built a “Commons”
    • Our Partners
    • Keeping Our Services Free
    • Talk to Us
  • Support Our
    Free Services
    • Donate Now
    • Many Ways to Give
    • Funding Initiatives
    • What Your Support Makes Possible
  • Facing
    Metastatic Cancer
    • Is Metastatic Cancer Curable?
    • Access to the Right Treatment
    • Registering with Cancer Commons
    • Enroll in XCELSIOR
    • Can a Virtual Tumor Board Help?
    • Get Help With Your Treatment Plan
  • New Cancer Research
    & Perspectives
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • Our Story
    • It Started in 1998…
    • We’re Here to Help
    • Why We Go to Work Each Day
    • Our Services
    • Meet the Team
    • Why we built a “Commons”
    • Our Partners
    • Keeping Our Services Free
    • Talk to Us
  • Support Our
    Free Services
    • Donate Now
    • Many Ways to Give
    • Funding Initiatives
    • What Your Support Makes Possible
  • Donate
 

Treatment Options

Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.

  • December 2, 2019 

    Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICMLBookmark

    George Lundberg, MD

    Continuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes: 

    Recent research findings can change practices for B-cell malignancies.

    Go to educational module at Clinical Care Options (requires free registration).

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    Pembrolizumab Plus Lenvatinib Approved for Endometrial CancerBookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain advanced endometrial cancers.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial CarcinomaBookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval for the drug erlofitinib in advanced urothelial malignancies that meet specific criteria.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney CancersBookmark

    George Lundberg, MD

    Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

    Go to full article published by Targeted Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    Ovarian Cancer: Is This the Beginning of the End?Bookmark

    George Lundberg, MD

    Article from Healio curated by Editor in Chief George Lundberg, MD, who notes: 

    This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.

    Go to full article published by Healio.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    FDA Approves Acalabrutinib for CLL/SLL as Part of Project OrbisBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    FDA Approves Therapy to Treat Patients with Relapsed and Refractory Mantle Cell Lymphoma Supported by Clinical Trial Results Showing High Response Rate of Tumor ShrinkageBookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.

    Go to full article published by the U.S. Food and Drug Administration (FDA).

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma PatientsBookmark

    George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019 

    Novel Agents Influence the Development of New Strategies for Treatment of Bladder CancerBookmark

    George Lundberg, MD

    Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Once bladder cancer has infiltrated the muscle wall in elderly patients, it becomes challenging to treat. New drugs and immunotherapies show some promise.

    Go to full article published by Targeted Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019 

    Microwave Ablation Feasible for cT1b Renal Cell CarcinomaBookmark

    George Lundberg, MD

    Article from Renal and Urology News curated by Editor in Chief George Lundberg, MD, who notes: 

    Microwave ablation has been shown to be a viable alternative to both radical and partial nephrectomy for kidney cancers that measure less than 7 cm in diameter. Outcomes for the two approaches are comparable.

    Go to full article published by Renal and Urology News.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • «
    • 1
    • …
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • …
    • 20
    • »

I’d already been leaning heavily towards a decision, and Emma helped me achieve the final decision…But Emma’s more than a scientist. She is a caring person.

Ellen
Breast cancer patient


You can makea differenceDonate

This free-of-charge, high-quality information service is a wonderful resource for patients with advanced cancer.

Hope S. Rugo, MD
UCSF Comprehensive Cancer Center

Cancer Commons is a nonprofit that provides hope to advanced cancer patients by helping them identify and access their best possible treatment. We offer a highly customized experience, connecting patients with our collaborative network of nurse navigators, PhD scientists, and national experts. We learn from every patient we serve, so we can help many more.

Don't miss Cancer Commons Connects
Exclusive monthly insights and stories—from and for our community

Working.

Get free advice on cancer treatment options

Patient Services

  • Get Access to the Right Treatment
  • Request an Options Report
  • Frequently Asked Questions (FAQ)

Perspectives

  • Latest Research & Perspectives
  • Treatment Options
  • Navigating Treatment
  • Living with Cancer
  • Patient Stories
  • Curious Dr. George
  • The Big Picture
  • COVID-19 and Cancer
  • Peer-Reviewed Publications

Organization

  • Our Story
  • The Team
  • Board of Directors
  • Advisory Board
  • The Commons
  • Partners
  • Expert Physician Advisors
  • Open Positions

Corporate & Regulatory

  • News and Events
  • Funding Initiatives
  • Contact Us
  • Cancer Commons International
  • Reports and Financials

Support & Giving

  • Donate
  • Other Ways to Give
  • Funding Initiatives
  • What Your Support Makes Possible
  • Testimonials


Donate

Cancer Commons
650 Castro Street, Suite 120-522
Mountain View, CA 94041, USA
650-289-4044

Patients Hotline

877-971-1200

If you have advanced or metastatic cancer, and you are a U.S. resident, our experts are here to help you identify the best-possible treatment options—all at no cost to you. Our one-on-one support is driven by the latest, evidence-based scientific discoveries.

To get started, simply fill out this form. You will then receive an email with a link to submit additional information.

  • Privacy Policy

© 2021 Cancer Commons.